Viemed Healthcare, Inc. · NASDAQ:VMD
Viemed Healthcare — Investor Presentation (November 2021)
22 slides from Viemed Healthcare's investor presentation, Nov 3, 2021
Slide 1: Leading the Healthcare Industry in Home Respiratory Care
LEADING THE HEALTHCARE INDUSTRY IN HOME RESPIRATORY CARE IR PRESENTATION / NOVEMBER 2021
Slide 2: Disclaimers and Other Important Information
DISCLAIMERS 2 Disclaimers and Other Important Information This presentation (the “Presentation”) about VieMed Healthcare, Inc. (“VieMed”) is dated as of November 2021. It is information in a summary form and does not purport to be complete. The data contained herein is derived from various internal
Slide 3: Viemed at a Glance
VieMed AT A GLANCE Largest independent specialized provider of non invasive ventilation (NIV) in the US home respiratory health care industry Highly profitable with a 45% CAGR in revenue growth since 2010 Service offering includes 24x7 in home respiratory care including specialized respiratory thera
Slide 4: Our Journey
V i e M e d D U A L - L I S T E D O N N A S D A Q Annual Revenues: $80.3M USD | 20 19 20 15 20 12 20 10 20 0 6 O U R J O U R N E Y V i e M e d U P L I S T I N G TO T S X Annual Revenues: $58.4M USD | 20 18 S L E E P M A N A G E M E N T F O U N D E D Annual Revenues: $0.24M USD | Respiratory DME spec
Slide 5: Key Investment Consideration
Specialized US based respiratory healthcare services company • Focused on Chronic Obstructive Pulmonary Disease (COPD) and growing aging population • $50 billion of annual healthcare cost in the U.S. spent on COPD Significant Market Growth Opportunity • 10,000 baby boomers are turning 65 every day (
Slide 6: Current State of the Industry
CURRENT STATE OF THE INDUSTRY The Medicare population is growing, with 60 million beneficiaries in 2018 and 69 million beneficiaries by 2023 At the age of 65, patients qualify for Medicare Expenditures are expected to grow at a 6% CAGR from $58.3 billion in 2019 to $98.4 billion in 2028 6
Slide 7: Market Share Held by Top Providers / NIV Market Penetration
MARKET SHARE HELD BY TOP 10 PROVIDERS VIEMED IS THIRD LARGEST PROVIDER 6 3 %10% *as of 2020 25 Million (estimated) people in the U.S. have COPD 2,500,000 or 10% have stage 4 COPD 1,250,000 or 50% of those with stage 4 COPD develop chronic respiratory failure becoming candidates for our therapy Appro
Slide 8: The Viemed Solution
Registered Respiratory Therapists (RTs) assigned to each patient and on call 24X7 • All RTs are COPD educators • Assess and service medical equipment • Overseen by pulmonologists on staff Each patient is given a customized in-home care plan based off Activities of Daily Living (ADLs) assessments. Su
Slide 9: A Dedicated 24/7 Respiratory Therapist
A D E D I C A T E D 24/7 R E S P I R A T O R Y T H E R A P I S T PERCUSSION VESTS OXYGEN THERAPY VENTILATORS COUGH ASSISTS comes w i th al l our VieMed products. SLEEP THERAPY 9 REMOTE PATIENT MONITORING
Slide 10: Proven Growth Strategy
Location selection • Based on high COPD rates • Target hospitals and facilities with high readmission rates and near existing service area • Leverage existing relationships and operate on the outskirts of large metropolitan areas Unique lean deployment model • No costly retail stores • Sales reps an
Slide 11: Anthem/Viemed Collaborative Pilot Real World Results
Anthem/VieMed Collaborative Pilot Real World Results
Slide 12: Technology & Remote Care Initiatives
Vision of becoming a leading healthcare technology company coupled with high touch human interaction in the home Goal is to improve quality of life and length of time patients spend with loved ones Increase efficiency of clinicians through improved remote workflow and proactive care patient engageme
Slide 13: Objectives for Next Months
OBJECTIVES FOR NEXT 24 MONTHS Grow active patient base while entering new target states through geographic expansion Promulgate findings from the growing number of research studies to referral sources and payors in order to save more lives and increase market penetration Diversify payor base – speci
Slide 14: Financials
FINANCIALS OO feMed
Slide 15: COVID-19 Update
COVID -19 UPDATE 15 • Continue business model of transitioning patients suffering from “traditional” disease states (COPD, ALS, etc.) out of acute facilities to the home with ventilation in order to free up valuable beds for COVID-19 patients • Served as a resource to States and health systems throu
Slide 16: Revenue Model
REVENUE MODEL Monthly rental fee – reimbursed by insurance and covered by Medicare Uncapped rental contract Average monthly client revenue is ~US$950 (all providers paid same rate by Medicare) Pricing includes equipment rental, RT service, supplies and maintenance of equipment 16
Slide 17: Historical Financial Performance
17 HISTORICAL FINANCIAL PERFORMANCE Adjusted EBITDA in USD * 2017 $11.3M 2018 $16.3M $19.4M 2019 2020 $41.3M $19.8M $45,000,000 $40,000,000 $35,000,000 $30,000,000 $25,000,000 $20,000,000 $15,000,000 $10,000,000 $5,000,000 $0 *See reconciliation in Appendix for Net Revenue and Adjusted EBITDA Active
Slide 18: Capital Markets Profile
CAPITAL MARKETS PROFILE 39,607,540 & 40,659,353 Shares outstanding & fully diluted* ~$26.9M 13% Inside ownership NASDAQ: VMD; TSX: VMD.TO Market cap as of October 31, 2021: ~$230M (USD) Stock price as of October 31, 2021: ~$5.73 (USD) Cash on hand in USD* Total LT debt in USD * ~$4.3 Total staff 608
Slide 19: Corporate Structure
CORPORATE STRUCTURE VieMed HealthCare Inc. (Canadian Parent Company Listed on NASDAQ & TSX) VieMed Inc. (Delaware Corporation/US Subsidiary) Home Sleep Delivered, LLC (US Subsidiary-Louisiana) Sleep Management, LLC (US Subsidiary- Louisiana) 19 VieMed Clinical Services, LLC (US Subsidiary-Louisiana)
Slide 20: Management Team & Board of Directors
Trae Fitzgerald Chief Financial Officer Casey Hoyt Chief Executive Officer and Director Randy Dobbs Chairman of the Board and Independent Director Todd Zehnder Chief Operating Officer and Director MANAGEMENT TEAM & BOARD OF DIRECTORS 20 Nitin Kaushal Independent Director Bruce Greenstein Independent
Slide 21: Thank you
Glen Akselrod Bristol Capital IR glen@bristolir.com Tel: 905 - 326 - 1888 Thank you 21
Slide 22: Appendix
Appendix (1) Net Revenue represents comparable presentation of bad debt expense netted within revenue, consistent with the 2019 adoption of ASC 842. Bad debt expense for years prior to 2019 was reported within selling, general, and administration expenses, consistent with ASC 840, which was supersed
Viemed Healthcare — Investor Presentation (November 2021) on 6ix